VANCOUVER, June 20, 2013 /CNW/ - CRH Medical Corporation (the "Company") (TSX: CRH) (OTCQX: CRMMF), announces that the nominees listed in the management proxy circular for the 2013 Annual Meeting of Shareholders were re-elected as directors.
A total of 14,991,244 common shares of the 48,764,914 shares outstanding were voted for the election of directors at the meeting, representing approximately 31% of the issued and outstanding common shares of the Company. Shareholders voted as follows:
|Nominee||Votes For||% Votes For||Votes Withheld||% Votes Withheld|
|Dr. Anthony Holler||8,399,132||56.15%||6,592,112||43.85%|
|Dr. Iain Cleator||14,519,544||97.03%||471,700||2.97%|
|Dr. David Johnson||8,429,232||56.33%||6,592,012||43.67%|
|Dr. Bergein Overholt||8,429,232||56.33%||6,592,012||43.67%|
In addition, KPMG LLP was appointed auditor of the Company for the coming year.
In light of the fact that nearly 70% of shares outstanding were not voted in respect of the election of directors, the Company intends to consider efforts to broaden shareholder participation in the voting process for its annual general meetings for the 2014 Annual Meeting of Shareholders.
About CRH Medical Corporation:
CRH Medical Corporation is North American company focused on providing physicians with innovative products for the treatment of gastrointestinal diseases. The Company's lead product, the CRH O'Regan System, is a single use, disposable, hemorrhoid treatment that is safe and highly effective in treating hemorrhoid grades I - IV. The O'Regan System is rapidly emerging as the standard of care with gastroenterologists who treat hemorrhoids. In addition to the product, CRH Medical delivers clinical, marketing and operational support directly to its partner physicians. CRH utilizes its web-based platform to connect doctors with patients as well as educating its ever increasing install base of physicians.
SOURCE: CRH Medical Corporation
For further information:
About CRH Medical Corporation, please contact: